NSCLC remains the leading cause of cancer-related mortality worldwide, with EGFR mutations being a critical driver in approximately 10-15% of lung adenocarcinomas in Western populations, and up to 40% ...
Many cases are driven by mutations in the EGFR gene, which causes cells to grow and divide uncontrollably. In Southeast Asia, these mutations are found in up to 40–60% of a common type of lung cancer ...
Patients with EGFR-mutated non-small cell lung cancer (NSCLC) who progressed on first-line osimertinib (Tagrisso) had better progression-free survival (PFS) in second line when they continued ...
Subcutaneous (SC) amivantamab reduces administration from hours to minutes, with efficacy and safety consistent with intravenous (IV) amivantamab1,2,3,4,5 ...
Older adults living with heart failure with preserved ejection fraction (HFpEF) are frequently labeled as having chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results